Rocket Pharmaceuticals

company

About

Rocket Pharmaceuticals is a biotech company that develops a pipeline of genetic therapies for rare childhood disorders.

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
$100.30M
Industries
Biotechnology,Genetics,Health Care,Pharmaceutical
Founded date
Jan 1, 2015
Number Of Employee
101 - 250
Operating Status
Active
Stock Symbol
nasdaq:RCKT
Legal Name
Rocket Pharmaceuticals, Inc.
Also Known As
Rocket Pharmaceuticals Ltd.

Rocket Pharmaceuticals is a biotechnology company that is working to develop first-in-class gene therapy treatments for rare and undertreated diseases. The Company's lead program is a lentiviral-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult-to-treat genetic disease that causes bone marrow failure and, in the worst-case scenario, cancer. Additional bone marrow-derived disorders are being studied in preclinical trials, including Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-1 (LAD-1), and Infantile Malignant Osteopetrosis. In addition, the company is working on an AAV-based gene therapy program for an unnamed rare pediatric disease.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
11
$653.05M
Rocket Pharmaceuticals has raised a total of $653.05M in funding over 2 rounds. Their latest funding was raised on Oct 3, 2022 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Oct 3, 2022 Post-IPO Equity $100.30M — — — Detail
Aug 30, 2021 Post-IPO Equity $26.40M 1 RTW Investments — Detail
Dec 9, 2020 Post-IPO Equity $299M 1 — — Detail
Nov 13, 2020 Grant $3.70M 1 California Institute of Regenerative Medicine (CIRM) — Detail
Dec 10, 2019 Post-IPO Equity $84.99M — — — Detail

Investors

Number of Lead Investors
Number of Investors
3
5
Rocket Pharmaceuticals is funded by 5 investors. RTW Investments and California Institute of Regenerative Medicine (CIRM) are the most recent investors.
Investor Name Lead Investor Funding Round
RTW Investments Yes Post-IPO Equity
California Institute of Regenerative Medicine (CIRM) Yes Grant
Frazier Healthcare Partners — Post-IPO Equity
Civilization Ventures — Post-IPO Equity
Sahsen Ventures — Post-IPO Equity

Employee Profiles

Number of Employee Profiles
10
Rocket Pharmaceuticals has 10 current employee profiles, including Executive Gaurav Shah
Executive
Executive
Executive
Executive
Executive

Acquisition

Rocket Pharmaceuticals has acquired 2 organizations. Their most recent acquisition was Inotek Pharmaceuticals on Sep 12, 2017. They acquired Inotek Pharmaceuticals for 0.

Date Company Name
Industry Acquisition Type Price
Biotechnology acquisition — Detail
Sep 20, 2022 Renovacor
Biotechnology acquisition — Detail